Triomics nabs $22M to bring oncology-specific AI to cancer centers

Source: TechCrunch

Funding round

Triomics, a startup building an AI‑powered platform to help oncologists and administrative staff automate data‑heavy tasks like clinical trial matching and appointment preparation, has raised $22 million in Series B funding. The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator, and others.

Problem and solution

Oncology breakthroughs are keeping patients alive longer, but the resulting dense, multi‑year medical records require extensive review by healthcare staff. A typical chart includes physician progress notes, imaging and pathology reports, and even scanned faxes. “We have seen medical records [with] thousands of pages of information,” Triomics co‑founder Sarim Khan told TechCrunch.

Triomics addresses this by generating verifiable patient summaries that surface key information directly inside the tools clinicians already use, eliminating the need to switch applications. By reducing appointment preparation time, these summaries give oncologists more time with patients and help alleviate staff burnout caused by complex patient histories.

The platform also automates the tedious task of submitting tumor reports to government registries—a legal mandate for cancer centers.

Company background

Founded in 2021, Triomics raised a $15 million Series A in mid‑2024. Initially focused on helping doctors identify the most suitable clinical trials for their patients, the company expanded its platform as large language model (LLM) capabilities grew, adding the patient‑summary feature described above.

Competition

Triomics’ most direct competition comes from AI medical scribes such as Abridge and Microsoft’s Nuance, which use AI to listen to and document patient‑doctor conversations for chart summarization. However, prominent institutions like Memorial Sloan Kettering (MSK) and Yale Cancer Center choose Triomics because its models are trained specifically on oncology data.

Growth

Despite fierce competition, Triomics is scaling rapidly. According to Khan, the startup expanded its enterprise customer base fourfold over the past year, driving a 10‑fold increase in annualized recurring revenue.